RU2009136669A - Лечение меланомы - Google Patents

Лечение меланомы Download PDF

Info

Publication number
RU2009136669A
RU2009136669A RU2009136669/15A RU2009136669A RU2009136669A RU 2009136669 A RU2009136669 A RU 2009136669A RU 2009136669/15 A RU2009136669/15 A RU 2009136669/15A RU 2009136669 A RU2009136669 A RU 2009136669A RU 2009136669 A RU2009136669 A RU 2009136669A
Authority
RU
Russia
Prior art keywords
melanoma
compound
group
tautomer
denotes
Prior art date
Application number
RU2009136669/15A
Other languages
English (en)
Russian (ru)
Inventor
Карла С. ХЕЙСИ (US)
Карла С. ХЕЙСИ
Пол ХОЛЛЕНБАХ (US)
Пол ХОЛЛЕНБАХ
Даниел МЕНЕЗЕШ (US)
Даниел МЕНЕЗЕШ
Нэнси ПРАЙЕР (US)
Нэнси ПРАЙЕР
Катерин РЕНДАЛ (US)
Катерин РЕНДАЛ
Марион ВИСМАНН (US)
Марион ВИСМАНН
Original Assignee
Новартис АГ (CH)
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39500684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2009136669(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис АГ (CH), Новартис Аг filed Critical Новартис АГ (CH)
Publication of RU2009136669A publication Critical patent/RU2009136669A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2009136669/15A 2007-03-09 2008-03-07 Лечение меланомы RU2009136669A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89404607P 2007-03-09 2007-03-09
US60/894,046 2007-03-09
US91140607P 2007-04-12 2007-04-12
US60/911,406 2007-04-12

Publications (1)

Publication Number Publication Date
RU2009136669A true RU2009136669A (ru) 2011-04-20

Family

ID=39500684

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009136669/15A RU2009136669A (ru) 2007-03-09 2008-03-07 Лечение меланомы

Country Status (11)

Country Link
US (1) US20100086518A1 (enExample)
JP (1) JP2010520881A (enExample)
KR (1) KR20090119768A (enExample)
AU (1) AU2008226582B2 (enExample)
BR (1) BRPI0808714A2 (enExample)
CA (1) CA2679268A1 (enExample)
CL (1) CL2008000681A1 (enExample)
MX (1) MX2009009574A (enExample)
RU (1) RU2009136669A (enExample)
TW (1) TW200843766A (enExample)
WO (1) WO2008112509A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
US8492374B2 (en) 2009-04-29 2013-07-23 Industrial Technology Research Institute Azaazulene compounds
US20120064008A1 (en) * 2009-05-20 2012-03-15 Bruce Zetter Compositions for the treatment of metastatic cancer and methods of use thereof
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
US8551479B2 (en) * 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP3060563B1 (en) 2013-10-25 2018-05-02 Novartis AG Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10495138B2 (en) 2014-09-29 2019-12-03 Hewlett-Packard Development Company, L.P. Hinge assembly with compressible sleeve
PL3200786T3 (pl) 2014-10-03 2020-03-31 Novartis Ag Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3103450A1 (en) * 2015-06-12 2016-12-14 Friedrich-Alexander-Universität Erlangen-Nürnberg None-hydrophobic compounds for use in treating metastasis and/or cartilage defect
US12006354B2 (en) 2017-05-24 2024-06-11 Novartis Ag Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer
CN108610293B (zh) * 2018-06-15 2020-08-04 南京工业大学 一种采用微通道反应装置制备多韦替尼中间体的方法
WO2024097855A2 (en) * 2022-11-03 2024-05-10 University Of Florida Research Foundation, Incorporated Identification of small molecules that recruit and activate rnase l

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838527B2 (en) * 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
JP4890255B2 (ja) * 2003-11-07 2012-03-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改良された薬物特性を有するキノリノン化合物の薬学的に受容可能な塩
AU2007272330A1 (en) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
WO2008013912A1 (en) * 2006-07-28 2008-01-31 Novartis Ag Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma

Also Published As

Publication number Publication date
CA2679268A1 (en) 2008-09-18
US20100086518A1 (en) 2010-04-08
TW200843766A (en) 2008-11-16
KR20090119768A (ko) 2009-11-19
CL2008000681A1 (es) 2008-10-24
MX2009009574A (es) 2009-09-16
WO2008112509A1 (en) 2008-09-18
AU2008226582A1 (en) 2008-09-18
BRPI0808714A2 (pt) 2014-08-12
AU2008226582B2 (en) 2011-07-21
JP2010520881A (ja) 2010-06-17

Similar Documents

Publication Publication Date Title
RU2009136669A (ru) Лечение меланомы
US6664264B2 (en) Thioether substituted imidazoquinolines
HUP0400710A2 (hu) Tioéter helyettesítővel helyettesített imidazokinolinszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
CA2481482A1 (en) Tropane derivatives as ccr5 modulators
RU2011141123A (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-b]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RAF-КИНАЗ
JP2019501195A5 (ja) 腫瘍を処置するための抗ｅｇｆｒ組み合わせ
RU2009120048A (ru) Способы и комбинированные средства для лечения болезни альцгеймера
JP2008526999A5 (enExample)
JP2006527776A5 (enExample)
NZ596739A (en) Methods of treating proliferative diseases
JP6240083B2 (ja) 樹状細胞癌ワクチンのための小分子エンハンサー
JP2013528174A5 (enExample)
RU2010154173A (ru) Режим введения нитрокатехолов
CN1360503A (zh) 用于治疗癌症的海鞘素743的组合物和用途
CN1606449A (zh) 抗肿瘤化合物在癌症治疗中的改良用途
JP2015522018A5 (enExample)
RU2017119064A (ru) Композиции апилимода и способы его использования при лечениии меланомы
RU2007143505A (ru) Производные ацетилена
RU2016127440A (ru) Производные тетрагидроимидазопиридина в качестве модуляторов активности tnf
PE20061193A1 (es) DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
RU2013130926A (ru) Комбинированная терапия, включающая вемурафениб и интерферон, для применения в лечении рака
WO2003072049A3 (en) Induction of hair growth with vascular endothelial growth factor
JPWO2020132661A5 (enExample)
RU2016110546A (ru) Комбинированная лекарственная терапия
US20100240595A1 (en) Improved Antitumoral Treatments

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20120618